In its upcoming report, Agilent Technologies (A) is predicted by Wall Street analysts to post quarterly earnings of $1.27 per share, reflecting a decline of 1.6% compared to the same period last year. Revenues are forecasted to be $1.67 billion, representing a year-over-year increase of 0.6%.
The current level reflects no revision in the consensus EPS estimate for the quarter over the past 30 days. This demonstrates how the analysts covering the stock have collectively reappraised their initial projections over this period.
Before a company announces its earnings, it is essential to take into account any changes made to earnings estimates. This is a valuable factor in predicting the potential reactions of investors toward the stock. Empirical research has consistently shown a strong correlation between trends in earnings estimate revisions and the short-term price performance of a stock.
While it's common for investors to rely on consensus earnings and revenue estimates for assessing how the business may have performed during the quarter, exploring analysts' forecasts for key metrics can yield valuable insights.
That said, let's delve into the average estimates of some Agilent metrics that Wall Street analysts commonly model and monitor.
The average prediction of analysts places 'Revenue by End Markets- Pharmaceutical' at $581.36 million. The estimate indicates a year-over-year change of +2.9%.
The collective assessment of analysts points to an estimated 'Revenue by End Markets- Academia and Government' of $143.37 million. The estimate indicates a year-over-year change of -4.4%.
Based on the collective assessment of analysts, 'Revenue by End Markets- Environmental and Forensics' should arrive at $163.16 million. The estimate suggests a change of -1.7% year over year.
Analysts predict that the 'Revenue by End Markets- Chemical and advanced materials' will reach $390.08 million. The estimate indicates a year-over-year change of -0.5%.
Analysts forecast 'Revenue by End Markets- Food' to reach $152.57 million. The estimate suggests a change of -2.8% year over year.
The combined assessment of analysts suggests that 'Revenue by End Markets- Diagnostics and Clinical' will likely reach $237.22 million. The estimate indicates a change of +4% from the prior-year quarter.
View all Key Company Metrics for Agilent here>>>
Shares of Agilent have demonstrated returns of -10.3% over the past month compared to the Zacks S&P 500 composite's +2.2% change. With a Zacks Rank #4 (Sell), A is expected to lag the overall market performance in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
Research Chief Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
This company targets millennial and Gen Z audiences, generating nearly $1 billion in revenue last quarter alone. A recent pullback makes now an ideal time to jump aboard. Of course, all our elite picks aren’t winners but this one could far surpass earlier Zacks’ Stocks Set to Double like Nano-X Imaging which shot up +129.6% in little more than 9 months.
Free: See Our Top Stock And 4 Runners UpAgilent Technologies, Inc. (A) : Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
